Chronic myelogenous leukemia, CML Karyotypic changes Ph(Philadelphia) chromosome: t(9: 22)(q34, ql1) C-abl-ber fusion genes/P210protein increased, dysregulated tyrosine kinase activity Prognosis Slow progression without treatment, median survival is 3 years Bone marrow transplantation STI-571: the exciting concept of designer drugs that specifically target oncoproteinsChronic myelogenous leukemia, CML Karyotypic changes Ph (Philadelphia) chromosome: t(9;22)(q34;q11) c-abl-ber fusion genes/P210protein: increased, dysregulated tyrosine kinase activity Prognosis Slow progression without treatment, median survival is 3 years Bone marrow transplantation STI-571: the exciting concept of designer drugs that specifically target oncoproteins